ALPN / Alpine Immune Sciences: November 2023 Data Release Could Get Ball Rolling

Alpine Immune Sciences, Inc. (ALPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks R more_horizontal

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative more_horizontal

Preliminary clinical data from the Alpine Immune Sciences, Inc. ongoing phase 3 RUBY-3 study will be presented at the American Society of Nephrology A more_horizontal

Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024. more_horizontal

Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one more_horizontal

Alpine Immune Sciences, Inc. (ALPN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentall more_horizontal

Alpine Immune has been riding on positive momentum surrounding its under-development drug program. more_horizontal

Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revision more_horizontal